New shot targets Virus-Linked cancers in early trial
NCT ID NCT07532746
First seen Apr 16, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This early-phase study tests a new drug called KSD-101 in 55 people with blood cancers linked to the Epstein-Barr virus that have returned or not improved with standard care. The main goals are to check safety and find the right dose, while also looking at whether the treatment can shrink tumors, reduce virus levels, and improve quality of life. Participants must be between 2 and 70 years old and have certain types of lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY EBV-ASSOCIATED HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-••••
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.